Apellis Pharmaceuticals Inc (NASDAQ: APLS) kicked off on Tuesday, down -1.86% from the previous trading day, before settling in for the closing price of $19.33. Over the past 52 weeks, APLS has traded in a range of $17.49-$53.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 92.54%. While this was happening, its average annual earnings per share was recorded 37.84%. With a float of $104.48 million, this company’s outstanding shares have now reached $124.50 million.
The extent of productivity of a business whose workforce counts for 710 workers is very important to gauge. In terms of profitability, gross margin is 84.82%, operating margin of -21.11%, and the pretax margin is -25.18%.
Apellis Pharmaceuticals Inc (APLS) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 16.76%, while institutional ownership is 99.41%. The most recent insider transaction that took place on Mar 17 ’25, was worth 4,543. In this transaction VP/Chief Accounting Officer of this company sold 183 shares at a rate of $24.82, taking the stock ownership to the 47,955 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Officer proposed sale 183 for $24.82, making the entire transaction worth $4,543.
Apellis Pharmaceuticals Inc (APLS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.84% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Take a look at Apellis Pharmaceuticals Inc’s (APLS) current performance indicators. Last quarter, stock had a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach 0.17 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
The latest stats from [Apellis Pharmaceuticals Inc, APLS] show that its last 5-days average volume of 2.6 million was superior to 2.01 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 29.58%. Additionally, its Average True Range was 1.46.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 8.14%, which indicates a significant decrease from 20.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.25% in the past 14 days, which was higher than the 59.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.83, while its 200-day Moving Average is $31.07. Now, the first resistance to watch is $19.55. This is followed by the second major resistance level at $20.13. The third major resistance level sits at $20.55. If the price goes on to break the first support level at $18.55, it is likely to go to the next support level at $18.13. Assuming the price breaks the second support level, the third support level stands at $17.55.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
The company with the Market Capitalisation of 2.38 billion has total of 125,516K Shares Outstanding. Its annual sales at the moment are 781,370 K in contrast with the sum of -197,880 K annual income. Company’s last quarter sales were recorded 212,530 K and last quarter income was -36,350 K.
